Dystonia Clinical Trial
Official title:
Cholinergic Receptor Imaging in Dystonia
Verified date | March 22, 2024 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Background: Dystonia is a movement disorder in which a person s muscles contract on their own. This causes different parts of the body to twist or turn. The cause of this movement is unknown. Researchers think it may have to do with a chemical called acetylcholine. They want to learn more about why acetylcholine in the brain doesn t work properly in people with dystonia. Objective: To better understand how certain parts of the brain take up acetylcholine in people with dystonia. Eligibility: Adults at least 18 years old who have DYT1 dystonia or cervical dystonia. Healthy adult volunteers. Design: Participants will be screened with a medical history, physical exam, and pregnancy test. Study visit 1: Participants will have a magnetic resonance imaging (MRI) scan of the brain. The MRI scanner is a metal cylinder in a strong magnetic field that takes pictures of the brain. Participants will lie on a table that slides in and out of the cylinder. Study visit 2: Participants will have a positron emission tomography (PET) scan. The PET scanner is shaped like a doughnut. Participants will lie on a bed that slides in and out of the scanner. A small amount of a radioactive chemical that can be detected by the PET scanner will be given through an IV line to measure how the brain takes up acetylcholine. ...
Status | Completed |
Enrollment | 31 |
Est. completion date | November 26, 2021 |
Est. primary completion date | November 26, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 100 Years |
Eligibility | - INCLUSION CRITERIA: Healthy research volunteers and adult patients with cervical dystonia will be eligible for the study. 1. Adult patients with cervical dystonia will have clinically documented cervical dystonia (focal cervical or segmental with neck involvement)established by history and physical/neurological examination. --Cervical dystonia patients must not have had received botulinum toxin injections into neck muscles for at least about 10 weeks at time of study participation 2. Healthy volunteers will be healthy subjects without neurological or psychiatric disorders (except for stable mild anxiety or stable mild depression) established by history and physical/neurological examination. 3. All participants will be at least 18 years of age. There is no maximum age limit. 4. Participants must be able to abstain from tobacco or nicotine replacement for at least 3 days prior to PET scan if participating in both MRI and PET scanning.. 5. Participants must be able to abstain from caffeine for at least 24 hours prior to PET scan if participating in both MRI and PET scanning. 6. Participants must be able to fast for 3 hours before PET scan if participanting in both MRI and PET scanning. EXCLUSION CRITERIA: 1. Subjects who are incapable of giving informed consent. 2. Employees of NINDS 3. Pregnant or breastfeeding women. Aside from history obtained at the screening, pregnancy status in women with childbearing potential is also established by urine pregnancy testing no more than 24 hours before each MRI and PET scan session. 4. Subjects with past or present medical history of (a) neurological disorders, such as stroke, movement disorders (other than cervical dystonia in the patient group), brain tumors, traumatic brain injury with loss of consciousness lasting more than a few seconds, ataxias, myopathies, myasthenia gravis, demyelinating diseases, alcoholism, drug dependence; (b) psychiatric disorders besides stable mild anxiety or stable mild depression, such as schizophrenia, major depressive and/or bipolar disorder, obsessive-compulsive disorder; (c) ventricular arrhythmias, renal and hepatic insufficiency, vascular headache, or carcinoid syndrome. 5. Abnormalities in neurological examination other what is typically associated with cervical dystonia, or any abnormalities in neurological examination in healthy volunteers. 6. Subjects who are currently taking oral medications known to affect muscarinic acetylcholine receptor binding in the central nervous system. Of note, some over-the counter-medications are known to affect muscarinic acetylcholine receptor binding. Subjects who use medications known to affect muscarinic acetylcholine receptor binding, such as first generation antihistamines for common cold and allergy symptoms and sleep aids for insomnia, occasionally on an as needed basis may be enrolled in this study. Furthermore, these as needed medications should be paused for at least 3 days before PET scanning. This three-day period is equivalent to about 4 to 5 half lives for these medications. In addition, subjects who use topical antimuscarinic medications, such as eye drops for glaucoma and inhalers, may be enrolled in this study because topical antimuscarinic medications have negligible systemic bioavailability. Subjects who have contraindications to MRI, ferromagnetic objects in their bodies (e.g., implanted stimulators including deep brain stimulation, aneurysm clips, prosthesis, artificial heart valves, etc.) that cannot be removed for the purpose of study participation. 7. Subjects who have claustrophobia. 8. Subjects who are unable to lie comfortably on their back for about one hour for MRI scanning (and about two hours for PET scanning if participating in both MRI and PET scanning). 9. Subjects with any radiation exposure in the past year that, together with the research PET scan, would exceed the NIH Radiation Safety Committee s annual limit (5 rem) if participating in both MRI and PET scanning. 10. Cervical dystonia patients who have cervical dystonia associated with trauma |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Institute of Neurological Disorders and Stroke (NINDS) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Characterize the M2 muscarinic acetylcholine receptor binding in DYT1 dystonia and cervical dystonia patients as measured with high-resolution positron emission tomography (PET) using [18F]FP-TZTP. | Characterization of the M2 muscarinic acetylcholine receptor binding in cervical dystonia patients as measured with high-resolution PET using [18F]FP-TZTP. | throughout protocol |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01433757 -
Ampicillin for DYT-1 Dystonia Motor Symptoms
|
Phase 1 | |
Recruiting |
NCT00971854 -
Alteration of Deep Brain Stimulation Parameters for Dystonia
|
N/A | |
Enrolling by invitation |
NCT00355927 -
Sedation During Microelectrode Recordings Before Deep Brain Stimulation for Movement Disorders.
|
N/A | |
Completed |
NCT00169338 -
Pallidal Stimulation in Patients With Post-anoxic and Idiopathic Dystonia
|
Phase 2 | |
Completed |
NCT00004421 -
Deep Brain Stimulation in Treating Patients With Dystonia
|
Phase 2/Phase 3 | |
Terminated |
NCT03270189 -
Effect of the Visual Information Change in Functional Dystonia
|
N/A | |
Recruiting |
NCT02583074 -
Clinical Trial of STN-DBS for Primary Cranial-Cervical Dystonia
|
N/A | |
Recruiting |
NCT06117020 -
Single and Multiple Ascending Dose Study of MTR-601 in Healthy Individuals
|
Phase 1 | |
Completed |
NCT01432899 -
Studying Childhood-Onset Hemidystonia
|
||
Completed |
NCT04948684 -
Efficacy of Botulinum Toxin for the Treatment of Dystonia Associated With Parkinson's Disease and Atypical Parkinsonism
|
||
Completed |
NCT05106816 -
The Effects of Vibrotactile Stimulation in Patients With Movement Disorders
|
N/A | |
Recruiting |
NCT05027997 -
Exploratory Study of Dipraglurant (ADX48621) for the Treatment of Patients With Blepharospasm
|
Phase 2 | |
Completed |
NCT00465790 -
Research of Biomarkers in Parkinson Disease
|
Phase 0 | |
Active, not recruiting |
NCT00142259 -
Efficacy and Safety of DBS of the GPi in Patients With Primary Generalized and Segmental Dystonia
|
Phase 4 | |
Recruiting |
NCT05663840 -
Effects of Exercise on Dystonia Pathophysiology
|
N/A | |
Not yet recruiting |
NCT06038097 -
Efficacy and Safety of Radiofrequency Pallidotomy in the Management of Dystonia
|
N/A | |
Recruiting |
NCT04286308 -
Cortical-Basal Ganglia Speech Networks
|
N/A | |
Active, not recruiting |
NCT03582891 -
The Motor Network in Parkinson's Disease and Dystonia: Mechanisms of Therapy
|
N/A | |
Completed |
NCT03318120 -
Exercise Training in Dystonia
|
N/A | |
Completed |
NCT04568681 -
Deep Brain Stimulation Effects in Dystonia
|